Health
Commonly-prescribed drug for IBD blunts COVID-19 vaccine response – News-Medical.Net
People who take a commonly-prescribed drug for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of COVID-19 vaccine, after…
People who take a commonly-prescribed drug for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of COVID-19 vaccine, after a large-scale study found many had poor antibody responses.
The research measured antibody responses after vaccination with the Pfizer/BioNTech or the Oxford/AstraZeneca COVID-19 vaccine in 865 people treated with infliximab, an anti-tumour necrosis factor (anti-TNF) biologic drug, prescribed to around two million people worldwide. Anti-TNF…
-
Noosa News22 hours agoInside the final hours before Australian lawyer Christopher Saines died in Thai massage parlour
-
General20 hours agoGerman backpacker Carolina Wilga found alive in WA’s outback
-
Business22 hours agoHow $1,000 a month in this ASX ETF could turn into $500,000
-
Noosa News22 hours agoGrow it local | Noosa Today